TetraPhase Pharmaceuticals Presents Data at ECCMID from Growing Portfolio of Next-Generation Antibiotic Candidates

Published: Apr 02, 2012

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results from studies that demonstrate the improved potency and pharmacokinetics of several of its newest discovery-stage tetracycline analogs. These data, which focus on significant gram-negative pathogens – including Pseudomonas aeruginosa, and troublesome gram-positive respiratory pathogens – were described in seven poster presentations at the 22nd European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in London, UK.

Back to news